Author(s): Santosh KS, Haruyo I, Gautam S, Ahn-Kwang-Seok, Bharat BA
Plumbagin, derived from the medicinal plant Plumbago zeylanica, modulates cellular proliferation, carcinogenesis, and radioresistance, all known to be regulated by the activation of the transcription factor NF-kappaB, suggesting plumbagin might affect the NF-kappaB activation pathway. We found that plumbagin inhibited NF-kappaB activation induced by TNF, and other carcinogens and inflammatory stimuli (e.g. phorbol 12-myristate 13-acetate, H2O2, cigarette smoke condensate, interleukin-1beta, lipopolysaccharide, and okadaic acid). Plumbagin also suppressed the constitutive NF-kappaB activation in certain tumor cells. The suppression of NF-kappaB activation correlated with sequential inhibition of the tumor necrosis factor (TNF)-induced activation of IkappaBalpha kinase, IkappaBalpha phosphorylation, IkappaBalpha degradation, p65 phosphorylation, p65 nuclear translocation, and the NF-kappaB-dependent reporter gene expression activated by TNF, TNFR1, TRAF2, NIK, IKK-beta, and the p65 subunit of NF-kappaB. Plumbagin also suppressed the direct binding of nuclear p65 and recombinant p65 to the DNA, and this binding was reversed by dithiothreitol both in vitro and in vivo. However, plumbagin did not inhibit p65 binding to DNA when cells were transfected with the p65 plasmid containing cysteine 38 mutated to serine. Plumbagin down-regulated the expression of NF-kappaB-regulated anti-apoptotic (IAP1, IAP2, Bcl-2, Bcl-xL, cFLIP, Bfl-1/A1, and survivin), proliferative (cyclin D1 and COX-2), and angiogenic (matrix metalloproteinase-9 and vascular endothelial growth factor) gene products. This led to potentiation of apoptosis induced by TNF and paclitaxel and inhibited cell invasion. Overall, our results indicate that plumbagin is a potent inhibitor of the NF-kappaB activation pathway that leads to suppression of NF-kappaB-regulated gene products. This may explain its cell growth modulatory, anticarcinogenic, and radiosensitizing effects previously described.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/16624823
Author(s): Takiar R, Nadayil D, Nandakumar A
Author(s): GM Cragg, DJ Newman
Author(s): Kumar S, Suresh PK, Vijayababu MR, Arunkumar A, Arunakaran J
Author(s): R Baral, Chattopadhyay U ( 2004) Neem (Azadirachtaindica) leaf mediated immune activation causes prophylactic growth inhibition of murine Ehrlich carcinoma and B16 melanoma
Author(s): Udeinya IJ,Shu EN, Quakyi I,Ajayi FO
Author(s): Othman F, Motalleb G,Peng SLT,Rahmat A, Fakurazi S, et al.
Author(s): Srivastava P, Yadav N, Lella R,Schneider A, Jones A, et al.
Author(s): Kavitha K, Priyadarsini RV, Anitha P, Ramalingam K,Sakthivel R, et al.
Author(s): Elumalai P, Gunadharini DN,Senthilkumar K, Banudevi S,Arunkumar R, et al.
Author(s): Sharma C, Andrea J, Goala P, Taher MG,Tahir AR, et al.
Author(s): Dale PS, Tamhankar CP, George D, Daftary GV ( 2001) Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects
Author(s): Popiela T, Kulig J, Hanisch J, Bock PR
Author(s): Tong-PengXu, HuaShen, Ling-Xiang Liu, Yong-QianShu
Author(s): Hsu YL, Cho CY, Kuo PL
Author(s): Kawiak A, Zawacka-Pankau J, Lojkowska E
Author(s): Liu X, Cai W, Niu M, Chong Y, Liu H, et al.
Author(s): Chen CA, Chang HH, Kao CY, Tsai TH, Chen YJ
Author(s): Prashar R, Kumar A, Banerjee S,Rao AR
Author(s): Prashar R, Kumar A, Hewer A, Cole KJ, Davis W
Author(s): Aruna K,Sivaramakrishnan VM
Author(s): Aruna K, Sivaramakrishnan VM
Author(s): Ganasoundari A, Uma Devi P,Rao BS
Author(s): Leyon PV, Kuttan G
Author(s): Singh N, Singh SM, Shrivastava P
Author(s): Singh SM, Singh N, Shrivastava P
Author(s): Kuo CL, Chou CC, Yung BY
Author(s): Ali H, Dixit S
Author(s): Pahadiya S, Sharma J
Author(s): Ueda JY, Tezuka Y, Banskota AH, Le Tran Q, Tran QK, et al.
Author(s): Wang S, Zheng Z, Weng Y, Yu Y, Zhang D, et al.
Author(s): Renault JH, Nuzillard JM, Le CrouÃ©rour G, ThÃ©penier P, ZÃ¨ches-Hanrot M, et al.